Therapeutic options for gastroesophageal cancer are limited, with only two targeted agents approved for the treatment of gastric and GEJ adenocarcinoma (neither agent is approved for the treatment of esophageal cancer). Roche/Genentech/Chugai’s Herceptin is the first-line standard of care for HER2 -positive metastatic patients, and Eli Lilly’s Cyramza is approved for use in advanced patients following fluoropyrimidine—and platinum-based therapy. The gastroesophageal cancer market is largely untapped and thus represents a lucrative opportunity for drug developers. The late-phase pipeline is buoyant; the eagerly anticipated emergence of multiple therapies such as Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb/Ono Pharmaceuticals) may soon offer gastroesophageal cancer patients a more optimistic outlook.
- How do current treatment practices differ between esophageal, gastric, and GEJ cancer, and which populations provide the greatest drug-treatment opportunities by geography?
- What are interviewed thought leaders’ insights on Herceptin, Cyramza, and chemotherapy?
- What clinical needs remained unfulfilled and what opportunities can developers capitalize on?
- Which immune checkpoint inhibitors (Keytruda, Opdivo, Bavencio, Yervoy) are forecast for approval in which disease setting, and how will they compete with currently marketed and established therapies?
- What are the market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.